Key result
Surgical excision and adjuvant therapy successfully treated two cases of primary cardiac sarcoma, yielding survival rates exceeding expectations.
Why the study?
Primary malignant cardiac tumors are exceedingly rare and dangerous, with no standardized practice guidelines developed due to their sheer rarity.
Case Report (n=2)
Demonstrates that surgical excision and adjuvant therapy can lead to better-than-expected survival in rare primary cardiac sarcomas.
Answers are grounded in this paper and cite their sources.
May support surgical excision plus adjuvant therapy in primary cardiac sarcoma; leaves open need for prospective validation in larger cohorts.
Primary malignant cardiac tumors are exceedingly rare and dangerous, often leading to very early death after initial symptom presentation. Each case poses a unique challenge, as no standardized practice guidelines have been developed due to their sheer rarity. Surgical excision and adjuvant therapy remain the mainstays of treatment. However, resection is impeded by the unique challenges of cardiac surgery and growth characteristics of the tumors, both contributing to high rates of recurrence. We present two cases of successfully treated primary cardiac sarcoma with survival rates exceeding expectations.
No takes yet. Share an insight, caveat, or question.
Kauzonas et al. (2020) conducted a case report in Primary cardiac sarcoma (n=2). Surgical excision and adjuvant therapy was evaluated on Survival. Surgical excision and adjuvant therapy successfully treated two cases of primary cardiac sarcoma, yielding survival rates exceeding expectations.
Synapse has enriched 10 related papers. Consider them for comparative context: